LifeMD Inc. Reports Fourth‑Quarter 2025 Results and Sets 2026 Revenue Target
LifeMD Inc. (Nasdaq: LFMD) announced its financial results for the fourth quarter and full year ended December 31, 2025, on March 9, 2026. The company, which operates a telehealth platform and sells over‑the‑counter products, disclosed a quarterly revenue of $45.8 million, a decline of 28.7 % from the $64.3 million reported in the same period a year earlier.
The company recorded a quarterly earnings‑per‑share (EPS) of ‑$0.066, slightly lower than the ‑$0.020 loss per share posted in the prior year’s quarter. EPS fell short of analyst expectations by $0.03.
Despite the revenue dip, LifeMD’s guidance for 2026 reflects strong growth expectations. Management set a $250 million+ annualized revenue run‑rate target for the fourth quarter of 2026, citing sustained demand for GLP‑1 therapies and expanded partnership agreements. The guidance level is above consensus estimates, indicating confidence in the company’s ability to rebound and capture additional market share.
Following the earnings release, the stock closed the next trading day at $3.12. The share price rose 11.5 % in the immediate aftermath of the announcement, reflecting positive investor sentiment toward the revised revenue outlook and partnership updates. LifeMD’s market capitalization stands at $144 million, and its price‑to‑earnings ratio is ‑18.242, consistent with the negative earnings reported for the period.
Key Points
| Item | Detail |
|---|---|
| Q4 2025 Revenue | $45.8 million (‑28.7 % YoY) |
| Q4 2025 EPS | ‑$0.066 |
| 2026 Revenue Target (Q4) | $250 million+ annualized |
| Stock Price (3 Mar 2026 close) | $3.12 |
| 52‑Week Range | $2.56 – $15.84 |
| Market Cap | $144 million |
| P/E Ratio | ‑18.242 |
Sources
- SeekingAlpha, March 9 2026 – “LifeMD outlines $250 M+ annualized revenue run rate target by Q4 2026 amid record GLP‑1 demand and expanded partnerships.”
- Benzinga, March 9 2026 – “LifeMD: Q4 Earnings Insights.”
- SeekingAlpha, March 9 2026 – “LifeMD rises on Q4 2025 beats, 2026 revenue guidance midpoint above consensus.”
- Investing.com (German), March 9 2026 – “LifeMD: Aktie legt nach Quartalszahlen und Ausblick um 11,5 % zu.”
- Investing.com (German), March 9 2026 – “LifeMD: EPS übertrifft Schätzungen um 0,03 $ – Umsatz schlechter als erwartet.”
- GlobeNewswire, March 9 2026 – “LifeMD, Inc.: LifeMD Reports Fourth Quarter and Full Year 2025 Results.”
- CEO.ca, March 9 2026 – “LifeMD Reports Fourth Quarter and Full Year 2025 Results.”
- Finanzen.net, March 8 2026 – “Ausblick: LifeMD gibt Ergebnis zum abgelaufenen Quartal bekannt.”
These developments highlight LifeMD’s ongoing challenges with declining quarterly revenue while underscoring management’s commitment to leveraging GLP‑1 demand and strategic partnerships to achieve a robust revenue trajectory in 2026.
